Total trials
622
Active
17
Phase 3
108
Total enrollment
121,928
Pipeline matrix
Showing 7 of 7 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Vehicle | — | — | — | 14 | |||
| Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free | — | — | — | — | — | 2 | |
| Aflibercept | — | — | — | — | — | 2 | |
| AR-14034 SR implant lower dose | — | — | — | — | — | 1 | |
| AR-14034 SR implant higher dose | — | — | — | — | — | 1 | |
| AR-14034 SR implant | — | — | — | — | — | 1 | |
| Sham procedure | — | — | — | — | — | 1 |
Next readouts
- 2027-02
- 2027-03
- 2027-05
Top conditions
- Ocular Hypertension98
- Cataract72
- Myopia61
- Dry Eye50
- Refractive Errors46
- Refractive Error44
- Glaucoma38
- Astigmatism35
Frequently asked questions about Alcon Research
- How many clinical trials does Alcon Research have on ClinicalTrials.gov?
- Alcon Research is listed as the lead sponsor on 622 clinical trials in ClinicalTrials.gov, 17 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Alcon Research's trials are in Phase 3?
- 108 of Alcon Research's trials are in Phase 3, spread across 7 active drug programs.
- What therapeutic areas does Alcon Research focus on?
- Alcon Research's most-studied conditions on ClinicalTrials.gov are Ocular Hypertension, Cataract, Myopia, Dry Eye, Refractive Errors.
- When are Alcon Research's next clinical trial readouts?
- Alcon Research has 3 upcoming primary-completion readouts tracked here; the soonest is “Efficacy and Safety of FID 123472 Ophthalmic Solution for Ocular Redness in Adults”, expected around 2027-02.